November 1, 1992

Cancer Research

OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH

VOLUME 52 • NO. 21 • PP 5853–6138

ISSN 0008-5472 • CNREA 8



8TH INTERNATIONAL SYMPOSIUM
ON PREVENTION AND DETECTION OF CANCER

COFACTOR INTERACTIONS AND CANCER PREVENTION

March 17-19, 1993 Nice, France

Call for Abstracts
Deadline: December 7, 1992

• Assessing interacting tumor promoting effects of genetic, hormonal, viral and environmental influences, and the role of immunity, diet, smoking, aging, oncogene amplification, tumor suppressor genes. • Focus on metabolic activation of carcinogens, disorders in signal transduction, clinical and laboratory identification of risk and prognosis, exposure assessment and intermediate endpoints. • Insights in effectiveness of cancer detection measures, intervention strategies, chemoprevention trials, risk reduction education.

Speakers: K Alitalo, University Finland; P Boyle, European School Oncology; W Cavanee, University California San Diego; R Flamant, Institute Gustave Roussy; H Fujiki, National Cancer Center Research Institute Japan; RA Good, University South Florida; MR Henderson, University Washington; LE Holm, Karolinska Hospital; J Horton, Albany Medical College; AB Miller, University of Toronto; R Montesano, International Agency Research Center; I Penn, University Cincinnati; F Perera, Columbia University; HC Pitot, University Wisconsin; EM Smith, University Iowa; MR Spitz, University Texas MD Anderson Cancer Center; TT Sun, Chinese Academy Medicine; H Vainio, International Agency Research Cancer; J Wahrendorf, German Cancer Research Center; IB Weinstein, Columbia University; D Zaridze, Cancer Research Center Russia.

For Information and Abstract Forms:
USA: Phone (508)-856-1822, Fax (508)-856-1824
Mme S Kay, UMMC, Box 20, 55 Lake Avenue North, Worcester MA 01655
FRANCE: Phone (33-93) 817133x2514, Fax (33-93) 533512
Mme F Fein, CAL, 36 Voie Romaine, F-06054 Nice Cedex

PRECEDING THE 8TH INTERNATIONAL SYMPOSIUM
ON PREVENTION AND DETECTION OF CANCER

GENETIC FACTORS IN PREDICTIVE AND PREVENTIVE ONCOLOGY

March 14-16, 1993 Nice, France

Call for Abstracts
Deadline: December 7, 1992

• Advances in molecular biology that highlight relevant insight into normal gene regulation and effects of gene mutations on cell kinetics and differentiation in cancer development including molecular markers of risk and prognosis, cofactors, polygenetic diseases, and identification of oncogenes and tumor suppressor genes. • Appraisal of data on genetic predisposition to cancer, epigenetic influences, gene transfer trials, signal transduction, multidrug resistance, genetics of metastasis and hereditary aspects of thyroid, breast, colorectal, lymphoid, CNS and other tumors.

Speakers: JF Bach, Necker Hospital; A Balmain, CRC Beatson Institute for Cancer Research; J Bernard, French Consultative Committee on Ethics in Life Sciences; JL Biedler, Memorial Sloan-Kettering Cancer Center; H de The, Hospital St Louis; T Dryja, Massachusetts Eye Ear Infirmary; M Feldman, Weizmann Institute Science; CC Harris, National Cancer Institute USA; JR Idle, University Newcastle Upon Tyne; P Kourilsky, Institute Pasteur; GM Lenoir, International Agency Research Cancer; HT Lynch, Creighton University School Medicine; MM Mareel, University Ghent; R Montesano, International Agency Research Cancer; JJ Mule, National Cancer Institute USA; C Mullen, National Cancer Institute USA; M Perricaudet, Institute Gustave Roussy; BAJ Ponder, University Cambridge; G Rouleau, McGill University; F Sigaux, Hospital St Louis; P Tambourin, Institute Curie; G Thomas, Institute Curie; HFA Vasen, University Hospital Utrecht.

For Information and Abstract Forms:
USA: Phone (508)-856-1822, Fax (508)-856-1824
Mme S Kay, UMMC, Box 20, 55 Lake Avenue North, Worcester MA 01655
FRANCE: Phone (33-93) 817133x2514, Fax (33-93) 533512
Mme F Fein, CAL, 36 Voie Romaine, F-06054 Nice Cedex

LEUKEMIA RESEARCH FOUNDATION GRANTS

The Leukemia Research Foundation, Inc. announces funds are available to support research in the field of leukemia. The goal of the grant program is to support new projects; preference will be given to applicants proposing new lines of investigation. Currently two types of grants are being funded; research grants, and postdoctoral fellowships. Grants and fellowships are for a one-year period, and may be renewable for a second year. DEADLINE FOR RECEIPT OF COMPLETED GRANT APPLICATIONS IS FEBRUARY 15, 1993.

Research Grant Policies:

1. Maximum budget request is $35,000. The funds may not be used for salary support of the principal investigator. Eligibility is restricted to investigators who are staff members of a university, hospital, or a non-profit research institute. The applicant must be less than five years beyond the end of training at the time of the proposed starting date of the grant award.
2. Eligibility is restricted to investigators who are staff members of a university, hospital, a non-profit research institute. The applicant must be less than five years beyond the end of training at the time of the proposed starting date of the grant award.

Postdoctoral Fellowship Policies:

1. Maximum budget request is $20,000. The funds usually are used to support the fellow's salary.
2. Eligibility is restricted to postdoctoral trainees with an M.D. or Ph.D. degree. The fellow must have no greater than three years of postdoctoral training at the time of the proposed starting date of the grant award.

For further information and applications, contact: **Hollis R. Brownstein, Chairman, Medical Advisory Committee, Leukemia Research Foundation, Inc., 899 Skokie Blvd. Suite LL14, Northbrook, IL 60062, Phone: 1-708-480-1177, Fax: 1-708-480-1417**

AACR SPECIAL CONFERENCE IN CANCER RESEARCH

CHEMICALS, MUTATIONS, AND CANCER

Co-Sponsored by the National Cancer Institute of Canada

December 7-12, 1992
Banff Springs Hotel, Banff, Alberta, Canada

CONFERENCE CHAIRPERSON
Lawrence A. Loeb / Seattle, WA

SCIENTIFIC PROGRAM

Keynote Address
Lawrence A. Loeb / Seattle, WA

Lesion Structure
John M. Essigmann / Cambridge, MA
Kenneth Breslauer / Piscataway, NJ
Paul Hopkins / Seattle, WA
Dinshaw J. Patel / New York, NY

The Biochemistry of Mutagenesis
G. Peter Beardsley / Cambridge, MA
Douglas E. Brash / New Haven, CT
Leonard C. Erickson / Maywood, IL
Arthur P. Grollman / Stony Brook, NY
B. Singer/ Berkeley, CA

DNA Damage and Mutations by Oxygen Free Radicals
Robert A. Floyd / Oklahoma City, OK
Max Costa / Tuxedo, NY
Shosuke Kawanishi / Kyoto, Japan
Lawrence J. Marnett / Nashville, TN
Susumu Nishimura / Tsukuba, Japan

Replication and Transcription
Philip C. Hanawalt / Stanford, CA
Harrison Echols / Berkeley, CA
Myron F. Goodman / Los Angeles, CA
Thomas A. Kunkel / Research Triangle Park, NC
Daniel Reines / Atlanta, GA

DNA Repair Diseases
Veronica M. Maher / East Lansing, MI
R. Stephen Lloyd / Nashville, TN
Roger A. Schultz / Baltimore, MD
Christine A. Weber / Livermore, CA
Malcolm C. Paterson / Edmonton, Canada

Endogenous Mutagenesis
Leona D. Samson / Boston, MA
Mark Meuth / Salt Lake City, UT
Jeffrey H. Miller / Los Angeles, CA
Roeland M. Schaaper / Research Triangle Park, NC
Mutsuo Sekiguchi / Fukuoka, Japan

Genomic Instability
Thea D. Tlsty / Chapel Hill, NC
Frederick W. Alt / New York, NY
Curtis C. Harris / Bethesda, MD
Bernard S. Strauss / Chicago, IL
Ted Weinert / Tucson, AZ

Genetic Homeostasis
Robert H. Haynes/ Toronto, Canada
Bruce Demple / Boston, MA
Carol A. Gross / Madison, WI
Peter Herrlich / Karlsruhe, Germany
Miroslav Radman/ Paris, France

Information and Application Forms

American Association for Cancer Research
Public Ledger Building
620 Chestnut Street, Suite 816
Philadelphia, PA 19106-3483

(215) 440-9300 (215) 440-9313 (FAX)

AMERICAN ASSOCIATION FOR CANCER RESEARCH
84th Annual Meeting
Michael B. Sporn, Program Chairperson
Orange County Civic Center, Orlando, FL
May 19-22, 1993

Plenary Sessions and Symposia: Titles and Chairpersons

Impact of Molecular Biology on Cancer: Its Detection, Prevention, and Treatment Joint AACR/ASCO Session - Stephen H. Friend

Transgenic Mice as Models for Cancer Pathogenesis Owen N. Witte

From Bench to Clinic: Concepts in the Design and Targeting of New Chemotherapeutic Agents Bruce A. Chabner

Invasion, Metastasis, and Angiogenesis Robert S. Kerbel

Mechanisms of Action of Chemopreventive Agents: Basic Science and Clinical Applications Martin Lipkin and Anita B. Roberts

Molecular Genetics of Drug Resistance June L. Biedler

Advances in Molecular Epidemiology of Human Cancer Curtis C. Harris

Cytokines in the Immunomodulation of Cancer Elizabeth A. Grimm

The Biology and Therapeutic Application of Normal Hematopoietic Stem Cells Malcolm A. S. Moore

The Restoration of Normal Differentiation and Growth to Preneoplastic and Neoplastic Cells: Strategies for Differentiation Therapy Waun Ki Hong

Nitric Oxide and Superoxide: Endogenous Mediators of DNA Damage Steven R. Tannenbaum

The Biology and Pathogenesis of Prostate Cancer Maarten C. Bosland

Vitamin D and Cancer Michael B. Sporn

Stromal-Epithelial (Paracrine) Influences on Neoplasia Gerald R. Cunha

Proteases and Carcinogenesis Lynn M. Matrisian

Strategies for Utilization of Tumor-specific Antisense Molecules or Ribozymes for the Control of Tumor Growth Jack S. Cohen

Biology and Genetics of Human Preneoplastic Lesions Walter N. Hittelman

Human DNA and Protein Adduct Dosimetry: Assessment of Risk for the Development of Primary and Secondary Cancers Regina M. Santella

Biology and Treatment of Pediatric Cancer Richard J. O'Reilly

Latest Advances in Tumor Suppressor Genes Edward E. Harlow

Immunologic Approaches to Targeted Therapy Ira Pastan

Molecular Basis for the Modulation of Radiation Sensitivity W. Gillies McKenna

Gene Rearrangements in Cancer Stanley J. Korsmeyer

Protein Phosphatases in Carcinogenesis Claude B. Klee

Protein Kinase C: Modulator of the Cancer Phenotype and Target for Chemotherapy Peter M. Blumberg

The EGF and FGF Receptor Superfamilies: Recent Advances in Ligands, Receptors, and Signal Transduction Andrew Baird and Michael Klagsbrun

---

Abstract Deadline: November 25, 1992

Further Information: AACR Office • Public Ledger Building • 620 Chestnut Street • Suite 816 • Philadelphia, PA 19106-3483
TELEPHONE (215) 440-9300 • **FAX** (215) 440-9313

AACR SPECIAL CONFERENCE IN CANCER RESEARCH

MECHANISM OF ACTION OF RETINOIDS, VITAMIN D, AND STEROID HORMONES

March 15-20, 1993
Banff Centre, Banff, Alberta, Canada

CONFERENCE CHAIRPERSONS
Michael B. Sporn / Bethesda, MD
Ronald M. Evans / San Diego, CA
David Mangelsdorf / San Diego, CA

PROGRAM COMMITTEE
Vincent Giguere / Toronto, Ontario, Canada
Morley Hollenberg / Calgary, Alberta, Canada
J. Wesley Pike / San Diego, CA

SCIENTIFIC PROGRAM

Keynote Address
Robert G. Roeder / New York, NY

DNA Binding/Heterodimers
Kazuhiko Umesono / San Diego, CA
Jeffrey D. Milbrandt / St. Louis, MO
Leonard P. Freedman / New York, NY
Christopher K. Glass / San Diego, CA
Magnus Pfahl / San Diego, CA

Three-Dimensional Structure of Receptors and Binding Proteins
Paul B. Sigler / New Haven, CT
Marcia Newcomer / Nashville, TN
Peter Wright / San Diego, CA

Development and Differentiation
David Mangelsdorf / San Diego, CA
Gregor Eichele / Houston, TX
Anita B. Roberts / Bethesda, MD

Genetic Regulation by Retinoids and Steroids
Lorraine J. Gudas / New York, NY
Vincent Giguere / Toronto, Canada

Vitamin D
J. Wesley Pike / San Diego, CA
Lise Binderup / Copenhagen, Denmark
Steven L. Teitelbaum / St. Louis, MO
Stavros Manolagas / Indianapolis, IN

Studies of Disease and Therapy
Anne Dejean / Paris, France
Bjorn Vennstrom / Stockholm, Sweden
Benjamin G. Neel / Boston, MA

Steroids and Related Receptors
Bert W. O'Malley / Houston, TX
Roger L. Miesfeld / Tucson, Arizona
Herbert H. Samuels / New York, NY

Metabolism of Retinoids
Joseph F. Grippo / Nutley, NJ
Robert R. Rando / Boston, MA
Richard Heyman / San Diego, CA

Information and Application Forms

American Association for Cancer Research
Public Ledger Building
620 Chestnut Street, Suite 816
Philadelphia, PA 19106-3483
(215) 440-9300 (215) 440-9313 (FAX)

COVER LEGEND



Cell Growth & Differentiation (*CG&D*), the new molecular biology journal published by the American Association for Cancer Research, was launched to provide a high quality forum for the publication of findings in the rapidly advancing fields of molecular, cellular, and developmental biology; molecular genetics; and biochemistry. *CG&D*'s broad scope, which is relevant to the interests of molecular biologists and cancer researchers, includes *in vitro* and *in vivo* studies of gene expression and regulation, growth factors and their receptors, signal transduction, and cell cycle control in normal and malignant cells and normal and abnormal development.

As Editor-in-Chief of *CG&D*, George F. Vande Woude heads an international Editorial Board of twenty-five distinguished scientists. Their expertise spans the merging disciplines that address the basis of normal cellular growth processes and oncogenesis. Prospective authors submit original manuscripts directly to any Editorial Board member for consideration for publication. This unique policy enables *CG&D* to maintain an average review time of three weeks and to publish manuscripts within ten weeks of acceptance. In addition, each issue of *CG&D* includes a Research Capsule, an invited article that summarizes and updates a specific topic of timeliness and significance.

Dr. Vande Woude brings to *CG&D* his world-renowned reputation as a scientist at the forefront of molecular biology and cancer research. He pioneered studies on the structure of acute transforming viruses and their role in cellular transformation. His demonstration that normal cellular genes can have transforming potential contributed to the conceptual framework for the study of activated oncogenes in human cancer. His research group examines the role of protooncogenes and oncogenes in normal and abnormal cells; its members discovered the human *met* oncogene and, recently, defined the *met* protooncogene as the receptor for hepatocyte growth factor. In addition, his research team's identification of the *met* locus provided a valuable marker for the isolation of the human cystic fibrosis gene. Further, Dr. Vande Woude's group cloned the *mos* protooncogene and continues to investigate the critical role of the mos protein in meiosis.

Dr. Vande Woude received his Ph.D. from Rutgers University. He served as a postdoctoral research associate and research chemist at the United States Department of Agriculture's Plum Island Animal Disease Laboratory. Since 1972, he has been associated with the National Cancer Institute as, variously, Head of the Human Tumor Studies Section, Head of the Virus Tumor Biochemistry Section, and Chief of the Laboratory of Molecular Oncology. In 1983, he assumed his present position as Director of the ABL-Basic Research Program, NCI-Frederick Cancer Research and Development Center.

Dr. Vande Woude has over 150 scientific publications, is a member of numerous professional associations and scientific advisory boards, and serves on the editorial boards of several scientific publications. A member of the National Cattlemen's Association, Dr. Vande Woude, along with his wife, Dot, owns and operates a small farm in Berryville, VA.

Pictured on the cover are Dr. Vande Woude and the September 1992 issue of *CG&D*.

Sidney Weinhouse